{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:05:31Z","timestamp":1772136331675,"version":"3.50.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004901","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de Minas Gerais","doi-asserted-by":"publisher","award":["RED-00314-16"],"award-info":[{"award-number":["RED-00314-16"]}],"id":[{"id":"10.13039\/501100004901","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004901","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de Minas Gerais","doi-asserted-by":"publisher","award":["RED-00314-16"],"award-info":[{"award-number":["RED-00314-16"]}],"id":[{"id":"10.13039\/501100004901","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004901","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de Minas Gerais","doi-asserted-by":"publisher","award":["RED-00314-16"],"award-info":[{"award-number":["RED-00314-16"]}],"id":[{"id":"10.13039\/501100004901","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004901","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de Minas Gerais","doi-asserted-by":"publisher","award":["RED-00314-16"],"award-info":[{"award-number":["RED-00314-16"]}],"id":[{"id":"10.13039\/501100004901","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004901","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de Minas Gerais","doi-asserted-by":"publisher","award":["RED-00314-16"],"award-info":[{"award-number":["RED-00314-16"]}],"id":[{"id":"10.13039\/501100004901","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Funda\u00e7\u00e3o Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100020987","name":"Universidade Federal de S\u00e3o Jo\u00e3o del-Rei","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020987","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-16870-0","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T18:23:54Z","timestamp":1759170234000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Molecular characterization of hereditary breast and ovarian cancer patients from a public precision medicine service in the Southeast Brazilian population"],"prefix":"10.1038","volume":"15","author":[{"given":"Andreza Am\u00e1lia de Freitas","family":"Ribeiro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thalia","family":"Queiroz Ladeira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus Vin\u00edcius","family":"Gon\u00e7alves Antunes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudemiro","family":"Pereira Neto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernanda","family":"Chaves de Freitas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabiana","family":"Castro de Faria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D\u00e9bora","family":"de Oliveira Lopes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Tarazona-Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciana","family":"Lara dos Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"16870_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"Cancer J. Clin."},{"key":"16870_CR2","unstructured":"INCA. Estimativa de 2023: Incid\u00eancia do C\u00e2ncer no Brasil. Instituto Nacional de C\u00e2ncer (INCA), ISBN 978-65-88517-10-9, (2022)."},{"key":"16870_CR3","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/S0959-8049(00)00110-6","volume":"36","author":"H Anton-Culver","year":"2000","unstructured":"Anton-Culver, H., Cohen, P. F., Gildea, M. E. & Ziogas, U. Characteristics of BRCA1 mutations in a population-based case series of breast and ovarian cancer. Eur. J. Cancer. 36, 1200\u20131208 (2000).","journal-title":"Eur. J. Cancer"},{"key":"16870_CR4","doi-asserted-by":"publisher","first-page":"19986","DOI":"10.1038\/s41598-019-55515-x","volume":"9","author":"E Jarhelle","year":"2019","unstructured":"Jarhelle, E. et al. Identifying sequence variants contributing to hereditary breast and ovarian cancer in BRCA1 and BRCA2 negative breast and ovarian cancer patients. Sci. Rep. 9, 19986 (2019).","journal-title":"Sci. Rep."},{"key":"16870_CR5","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1002\/ijc.31992","volume":"144","author":"S Schubert","year":"2019","unstructured":"Schubert, S. et al. The identification of pathogenic variants in BRCA1\/2 negative, high risk, hereditary breast and\/or ovarian cancer patients: High frequency of FANCM pathogenic variants. Int. J. Cancer 144, 2683\u20132694 (2019).","journal-title":"Int. J. Cancer"},{"key":"16870_CR6","doi-asserted-by":"publisher","first-page":"8696","DOI":"10.1073\/pnas.1504447112","volume":"112","author":"FSG Kehdy","year":"2015","unstructured":"Kehdy, F. S. G. et al. Origin and dynamics of admixture in Brazilians and its effect on the pattern of deleterious mutations. Proc. Natl. Acad. Sci. 112, 8696\u20138701 (2015).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"16870_CR7","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1186\/s12885-019-5756-4","volume":"19","author":"GN Tsaousis","year":"2019","unstructured":"Tsaousis, G. N. et al. Analysis of hereditary cancer syndromes by using a panel of genes: Novel and multiple pathogenic mutations. BMC Cancer 19, 535 (2019).","journal-title":"BMC Cancer"},{"key":"16870_CR8","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1002\/cncr.32910","volume":"10","author":"M Mutebi","year":"2020","unstructured":"Mutebi, M. et al. Breast cancer treatment: A phased approach to implementation. Cancer 126 Suppl. 10, 2365\u20132378 (2020).","journal-title":"Cancer 126 Suppl."},{"key":"16870_CR9","unstructured":"IBGE. Pesquisa nacional de sa\u00fade 2019: Ciclos de vida. Instituto Brasileiro de Geografia e Estat\u00edstica (IBGE). ISBN 978-65-87201-76-4. 139p, (2021)."},{"key":"16870_CR10","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1470-2045(13)70048-2","volume":"14","author":"PE Goss","year":"2013","unstructured":"Goss, P. E. et al. Planning cancer control in Latin America and the Caribbean. Lancet Oncol. 14, 391\u2013436 (2013).","journal-title":"Lancet Oncol."},{"key":"16870_CR11","doi-asserted-by":"publisher","first-page":"100631","DOI":"10.1016\/j.lana.2023.100631","volume":"28","author":"F Ortega","year":"2023","unstructured":"Ortega, F. & Pele, A. Brazil\u2019s unified health system: 35 years and future challenges. Lancet Reg. Health \u2013 Americas. 28, 100631 (2023).","journal-title":"Lancet Reg. Health \u2013 Americas"},{"key":"16870_CR12","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s40001-024-01767-x","volume":"29","author":"AA de Freitas Ribeiro","year":"2024","unstructured":"de Freitas Ribeiro, A. A., Junior, N. M. C. & dos Santos, L. L. Systematic review of the molecular basis of hereditary breast and ovarian cancer syndrome in brazil: The current scenario. Eur. J. Med. Res. 29, 187 (2024).","journal-title":"Eur. J. Med. Res."},{"key":"16870_CR13","doi-asserted-by":"publisher","first-page":"80465","DOI":"10.18632\/oncotarget.12610","volume":"7","author":"GC Fernandes","year":"2016","unstructured":"Fernandes, G. C. et al. Prevalence of BRCA1\/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry. Oncotarget 7, 80465\u201380481 (2016).","journal-title":"Oncotarget"},{"key":"16870_CR14","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cancergen.2016.06.008","volume":"209","author":"B Alemar","year":"2016","unstructured":"Alemar, B. et al. Prevalence of hispanic BRCA1 and BRCA2 mutations among hereditary breast and ovarian cancer patients from Brazil reveals differences among Latin American populations. Cancer Genet. 209, 417\u2013422 (2016).","journal-title":"Cancer Genet."},{"key":"16870_CR15","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1186\/s12885-016-2966-x","volume":"16","author":"S Maistro","year":"2016","unstructured":"Maistro, S. et al. Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil. BMC Cancer. 16, 934 (2016).","journal-title":"BMC Cancer"},{"key":"16870_CR16","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s12282-018-00938-z","volume":"26","author":"NM Cipriano","year":"2019","unstructured":"Cipriano, N. M. et al. Mutation screening of TP53, CHEK2 and BRCA genes in patients at high risk for hereditary breast and ovarian cancer (HBOC) in Brazil. Breast Cancer. 26, 397\u2013405 (2019).","journal-title":"Breast Cancer"},{"key":"16870_CR17","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s10689-015-9858-0","volume":"15","author":"ES de Oliveira","year":"2016","unstructured":"de Oliveira, E. S. et al. Screening of the BRCA1 gene in Brazilian patients with breast and\/or ovarian cancer via high-resolution melting reaction analysis. Fam. Cancer. 15, 173\u2013181 (2016).","journal-title":"Fam. Cancer"},{"key":"16870_CR18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.6004\/jnccn.2021.0001","volume":"19","author":"MB Daly","year":"2021","unstructured":"Daly, M. B. et al. Genetic\/Familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Canc. Netw. 19, 77\u2013102 (2021).","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"16870_CR19","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.6004\/jnccn.2023.0051","volume":"21","author":"MB Daly","year":"2023","unstructured":"Daly, M. B. et al. NCCN guidelines\u00ae insights: Genetic\/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2024: featured updates to the NCCN guidelines. J. Natl. Compr. Canc. Netw. 21, 1000\u20131010 (2023).","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"16870_CR20","unstructured":"IBGE. Censo Instituto Brasileiro de Geografia e Estat\u00edstica (IBGE). 2022. (2022). https:\/\/www.ibge.gov.br\/estatisticas\/sociais\/trabalho\/22827-censo-demografico-2022.html"},{"key":"16870_CR21","unstructured":"IBGE. \u00c1reas Territoriais. Instituto Brasileiro de Geografia e Estat\u00edstica (IBGE). (2023). https:\/\/www.ibge.gov.br\/geociencias\/organizacao-do-territorio\/estrutura-territorial\/15761-areas-dos-municipios.html"},{"key":"16870_CR22","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1590\/1678-4685-gmb-2018-0076","volume":"42","author":"AM de Souza","year":"2019","unstructured":"de Souza, A. M., Resende, S. S., de Sousa, T. N. & Brito C.F.A. A systematic scoping review of the genetic ancestry of the Brazilian population. Genet. Mol. Biol. 42, 495\u2013508 (2019).","journal-title":"Genet. Mol. Biol."},{"key":"16870_CR23","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1002\/ajmg.c.31853","volume":"184","author":"SDJ Pena","year":"2020","unstructured":"Pena, S. D. J., Santos, F. R. & Tarazona-Santos, E. Genetic admixture in Brazil. Am. J. Med. Genet. Part. C: Seminars Med. Genet. 184, 928\u2013938 (2020).","journal-title":"Am. J. Med. Genet. Part. C: Seminars Med. Genet."},{"key":"16870_CR24","unstructured":"IBGE & Brasil 500 anos de povoamento. Instituto Brasileiro de Geografia e Estat\u00edstica (IBGE). https:\/\/brasil500anos.ibge.gov.br\/"},{"key":"16870_CR25","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.cancergen.2015.11.003","volume":"209","author":"H Schayek","year":"2016","unstructured":"Schayek, H. et al. The rate of recurrent BRCA1, BRCA2, and TP53 mutations in the general population, and unselected ovarian cancer cases, in belo horizonte, Brazil. Cancer Genet. 209, 50\u201352 (2016).","journal-title":"Cancer Genet."},{"key":"16870_CR26","doi-asserted-by":"publisher","first-page":"074","DOI":"10.1055\/s-0042-1757956","volume":"45","author":"CM de Carvalho","year":"2023","unstructured":"de Carvalho, C. M., Braga, L. C., Silva, L. M., Chami, A. M. & Filho, A. L. S. Germline mutations landscape in a cohort of the state of Minas gerais, brazil, in patients who underwent genetic counseling for gynecological and breast cancer. Revista Brasileira De Ginecol. E Obstetr\u00edcia. 45, 074\u2013081 (2023).","journal-title":"Revista Brasileira De Ginecol. E Obstetr\u00edcia"},{"key":"16870_CR27","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s10549-024-07383-x","volume":"207","author":"JP Faria","year":"2024","unstructured":"Faria, J. P. et al. Spectrum of germline pathogenic variants in Brazilian hereditary breast\/ovarian cancer cases. Breast Cancer Res. Treat. 207, 615\u2013624 (2024).","journal-title":"Breast Cancer Res. Treat."},{"key":"16870_CR28","doi-asserted-by":"publisher","first-page":"4190","DOI":"10.1038\/s41598-022-07383-1","volume":"12","author":"RSC Guindalini","year":"2022","unstructured":"Guindalini, R. S. C. et al. Detection of germline variants in Brazilian breast cancer patients using multigene panel testing. Sci. Rep. 12, 4190 (2022).","journal-title":"Sci. Rep."},{"key":"16870_CR29","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s10549-022-06560-0","volume":"193","author":"GES Felix","year":"2022","unstructured":"Felix, G. E. S. et al. Mutational spectrum of breast cancer susceptibility genes among women ascertained in a cancer risk clinic in Northeast Brazil. Breast Cancer Res. Treat. 193, 485\u2013494 (2022).","journal-title":"Breast Cancer Res. Treat."},{"key":"16870_CR30","doi-asserted-by":"publisher","first-page":"932957","DOI":"10.3389\/fonc.2022.932957","volume":"12","author":"ACLVC Gifoni","year":"2022","unstructured":"Gifoni, A. C. L. V. C. et al. Hereditary breast cancer in the Brazilian state of Cear\u00e1 (The CHANCE Cohort): Higher-than-expected prevalence of recurrent germline pathogenic variants. Front. Oncol. 12, 932957 (2022).","journal-title":"Front. Oncol."},{"key":"16870_CR31","doi-asserted-by":"publisher","first-page":"18629","DOI":"10.1038\/s41598-022-23012-3","volume":"12","author":"BP Matta","year":"2022","unstructured":"Matta, B. P. et al. Familial history and prevalence of BRCA1, BRCA2 and TP53 pathogenic variants in HBOC Brazilian patients from a public healthcare service. Sci. Rep. 12, 18629 (2022).","journal-title":"Sci. Rep."},{"key":"16870_CR32","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12920-019-0652-y","volume":"13","author":"C da Silva","year":"2020","unstructured":"da Silva, C. et al. Germline variants in DNA repair genes associated with hereditary breast and ovarian cancer syndrome: Analysis of a 21 gene panel in the Brazilian population. BMC Med. Genom. 13, 21 (2020).","journal-title":"BMC Med. Genom."},{"key":"16870_CR33","doi-asserted-by":"publisher","first-page":"e0247363","DOI":"10.1371\/journal.pone.0247363","volume":"16","author":"RL Sandoval","year":"2021","unstructured":"Sandoval, R. L. et al. Germline molecular data in hereditary breast cancer in brazil: Lessons from a large single-center analysis. PLOS ONE 16, e0247363 (2021).","journal-title":"PLOS ONE"},{"key":"16870_CR34","doi-asserted-by":"publisher","first-page":"e20190072","DOI":"10.1590\/\/1678-4685-gmb-2019-0072","volume":"43","author":"R Gomes","year":"2020","unstructured":"Gomes, R. et al. Haplotypic characterization of BRCA1 c.5266dupC, the prevailing mutation in Brazilian hereditary breast\/ovarian cancer. Genet. Mol. Biol. 43, e20190072 (2020).","journal-title":"Genet. Mol. Biol."},{"key":"16870_CR35","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s10549-018-4938-0","volume":"172","author":"AR de Souza Timoteo","year":"2018","unstructured":"de Souza Timoteo, A. R. et al. A portrait of germline mutation in Brazilian at-risk for hereditary breast cancer. Breast Cancer Res. Treat. 172, 637\u2013646 (2018).","journal-title":"Breast Cancer Res. Treat."},{"key":"16870_CR36","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s10549-023-06892-5","volume":"199","author":"P Mazzonetto","year":"2023","unstructured":"Mazzonetto, P. et al. BRCA1 and BRCA2 germline mutation analysis from a cohort of 1267 patients at high risk for breast cancer in Brazil. Breast Cancer Res. Treat. 199, 127\u2013136 (2023).","journal-title":"Breast Cancer Res. Treat."},{"key":"16870_CR37","doi-asserted-by":"publisher","first-page":"632870","DOI":"10.1155\/2011\/632870","volume":"2011","author":"A Farooq","year":"2011","unstructured":"Farooq, A., Naveed, A. K., Azeem, Z. & Ahmad, T. Breast and ovarian cancer risk due to prevalence of BRCA1 and BRCA2 variants in Pakistani population: A Pakistani database report. J. Oncol. 2011, 632870 (2011).","journal-title":"J. Oncol."},{"key":"16870_CR38","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s10549-018-4887-7","volume":"172","author":"I Barnes-Kedar","year":"2018","unstructured":"Barnes-Kedar, I. et al. The yield of full BRCA1\/2 genotyping in Israeli high-risk breast\/ovarian cancer patients who do not carry the predominant mutations. Breast Cancer Res. Treat. 172, 151\u2013157 (2018).","journal-title":"Breast Cancer Res. Treat."},{"key":"16870_CR39","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1007\/s10549-012-2159-5","volume":"134","author":"H Kim","year":"2012","unstructured":"Kim, H. et al. Characteristics and spectrum of BRCA1 and BRCA2 mutations in 3,922 Korean patients with breast and ovarian cancer. Breast Cancer Res. Treat. 134, 1315\u20131326 (2012).","journal-title":"Breast Cancer Res. Treat."},{"key":"16870_CR40","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s10549-014-3218-x","volume":"149","author":"E Rosenthal","year":"2015","unstructured":"Rosenthal, E., Moyes, K., Arnell, C., Evans, B. & Wenstrup, R. J. Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry. Breast Cancer Res. Treat. 149, 223\u2013227 (2015).","journal-title":"Breast Cancer Res. Treat."},{"key":"16870_CR41","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/humu.23406","volume":"39","author":"TR Rebbeck","year":"2018","unstructured":"Rebbeck, T. R. et al. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum. Mutat. 39, 593\u2013620 (2018).","journal-title":"Hum. Mutat."},{"key":"16870_CR42","doi-asserted-by":"publisher","first-page":"e0187630","DOI":"10.1371\/journal.pone.0187630","volume":"12","author":"B Alemar","year":"2017","unstructured":"Alemar, B. et al. BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern brazil: Are international testing criteria appropriate for this specific population?. PLOS ONE 12, e0187630 (2017).","journal-title":"PLOS ONE"},{"key":"16870_CR43","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.canlet.2007.10.044","volume":"261","author":"EI Palmero","year":"2008","unstructured":"Palmero, E. I. et al. Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil. Cancer Lett. 261, 21\u201325 (2008).","journal-title":"Cancer Lett."},{"key":"16870_CR44","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s10549-006-9378-6","volume":"103","author":"MCB Gomes","year":"2007","unstructured":"Gomes, M. C. B. et al. Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Brazil. Breast Cancer Res. Treat. 103, 349\u2013353 (2007).","journal-title":"Breast Cancer Res. Treat."},{"key":"16870_CR45","first-page":"505","volume":"60","author":"D Abeliovich","year":"1997","unstructured":"Abeliovich, D. et al. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am. J. Hum. Genet. 60, 505\u2013514 (1997).","journal-title":"Am. J. Hum. Genet."},{"key":"16870_CR46","doi-asserted-by":"publisher","first-page":"9188","DOI":"10.1038\/s41598-018-27315-2","volume":"8","author":"EI Palmero","year":"2018","unstructured":"Palmero, E. I. et al. The germline mutational landscape of BRCA1 and BRCA2 in Brazil. Sci. Rep. 8, 9188 (2018).","journal-title":"Sci. Rep."},{"key":"16870_CR47","first-page":"101","volume":"25","author":"RA Eeles","year":"1995","unstructured":"Eeles, R. A. Germline mutations in the TP53 gene. Cancer Surv. 25, 101\u2013124 (1995).","journal-title":"Cancer Surv."},{"key":"16870_CR48","first-page":"5358","volume":"48","author":"FP Li","year":"1988","unstructured":"Li, F. P. et al. A cancer family syndrome in twenty-four kindreds. Cancer Res. 48, 5358\u20135362 (1988).","journal-title":"Cancer Res."},{"key":"16870_CR49","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.cancergen.2018.09.001","volume":"228","author":"PS Felicio","year":"2018","unstructured":"Felicio, P. S. et al. Screening and characterization of BRCA2 c.156_157insAlu in Brazil: Results from 1380 individuals from the South and Southeast. Cancer Genetics 228, 93\u201397 (2018).","journal-title":"Cancer Genetics"},{"key":"16870_CR50","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1023\/A:1004099605261","volume":"108","author":"DJ Rowold","year":"2000","unstructured":"Rowold, D. J. & Herrera, R. J. Alu elements and the human genome. Genetica 108, 57\u201372 (2000).","journal-title":"Genetica"},{"key":"16870_CR51","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s10689-012-9551-5","volume":"11","author":"MAM Moreira","year":"2012","unstructured":"Moreira, M. A. M. et al. Portuguese c.156_157insAlu BRCA2 founder mutation: Gastrointestinal and tongue neoplasias may be part of the phenotype. Fam. Cancer 11, 657\u2013660 (2012).","journal-title":"Fam. Cancer"},{"key":"16870_CR52","doi-asserted-by":"publisher","first-page":"4782","DOI":"10.1158\/1078-0432.CCR-22-1483","volume":"28","author":"W Park","year":"2022","unstructured":"Park, W. et al. Clinico-genomic characterization of ATM and HRD in pancreas cancer: Application for practice. Clin. Cancer Res. 28, 4782\u20134792 (2022).","journal-title":"Clin. Cancer Res."},{"key":"16870_CR53","doi-asserted-by":"publisher","first-page":"727","DOI":"10.3390\/genes12050727","volume":"12","author":"LS Stucci","year":"2021","unstructured":"Stucci, L. S. et al. The ATM gene in breast cancer: Its relevance in clinical practice. Genes 12, 727 (2021).","journal-title":"Genes"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16870-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16870-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16870-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:02:49Z","timestamp":1759172569000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16870-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["16870"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-16870-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6457826\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"15 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare no competing interests.\u00a0The authors have given their consent for the publication of this manuscript. All patients voluntarily agreed to participate in this study by signing an informed consent form, which was approved by the ethics committee of our institution.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Contest for publication"}},{"value":"This study received approval from the Ethics Committee of S\u00e3o Jo\u00e3o de Deus Hospital (approval number 45662921.9.0000.5545). All participants provided written informed consent prior to inclusion, and all procedures were carried out in compliance with applicable ethical standards and regulations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}],"article-number":"33495"}}